New Therapeutic Vaccination Strategies for the Treatment of Chronic Hepatitis B

Overview

Journal Virol Sin

Specialty Microbiology

Date 2014 Jan 24

PMID 24452539

Citations 27

Authors

Jia Liu

Anna Kosinska

Mengji Lu

Michael Roggendorf

Affiliations

Soon will be listed here.

Abstract

Chronic hepatitis B virus (CHB) is currently treated with either interferon-based or nucleot(s)ide-based antiviral therapies. However, treatment with pegylated interferon alpha results in a durable antiviral response in only about 30% patients and is associated with side effects. Most patients receiving nucleot(s)ide analogue treatment do not establish long-term, durable control of infection and have rebounding viremia after cessation of therapy. Thus, novel therapy strategies are necessary to achieve the induction of potent and durable antiviral immune responses of the patients which can maintain long-term control of viral replication. Therapeutic vaccination of HBV carriers is a promising strategy for the control of hepatitis B. Here the authors review new therapeutic vaccination strategies to treat chronic hepatitis B which may be introduced for patient treatment in the future.

Citing Articles

Evaluation of the Effect of CD70 Co-Expression on CD8 T Cell Response in Protein-Prime MVA-Boost Vaccination in Mice.

Stephan A, Kosinska A, Muck-Hausl M, Muschaweckh A, Jager C, Roder N Vaccines (Basel). 2023; 11(2).

PMID: 36851121 PMC: 9966001. DOI: 10.3390/vaccines11020245.

IFNα subtype-specific susceptibility of HBV in the course of chronic infection.

Xie X, Karakoese Z, Ablikim D, Ickler J, Schuhenn J, Zeng X Front Immunol. 2022; 13:1017753.

PMID: 36311794 PMC: 9616162. DOI: 10.3389/fimmu.2022.1017753.

A Therapeutic Hepatitis B Virus DNA Vaccine Induces Specific Immune Responses in Mice and Non-Human Primates.

De Pooter D, Van Gulck E, Chen A, Evans C, Neefs J, Horton H Vaccines (Basel). 2021; 9(9).

PMID: 34579206 PMC: 8471825. DOI: 10.3390/vaccines9090969.

The Functional and Antiviral Activity of Interferon Alpha-Inducible IFI6 Against Hepatitis B Virus Replication and Gene Expression.

Sajid M, Ullah H, Yan K, He M, Feng J, Shereen M Front Immunol. 2021; 12:634937.

PMID: 33868257 PMC: 8047077. DOI: 10.3389/fimmu.2021.634937.

Advanced Therapeutics, Vaccinations, and Precision Medicine in the Treatment and Management of Chronic Hepatitis B Viral Infections; Where Are We and Where Are We Going?.

Duraisamy G, Bhosale D, Lipenska I, Huvarova I, Ruzek D, Windisch M Viruses. 2020; 12(9).

PMID: 32906840 PMC: 7552065. DOI: 10.3390/v12090998.

References

Hervas-Stubbs S, Lasarte J, Sarobe P, Vivas I, Condreay L, Cullen J . T-helper cell response to woodchuck hepatitis virus antigens after therapeutic vaccination of chronically-infected animals treated with lamivudine. J Hepatol. 2001; 35(1):105-11. DOI: 10.1016/s0168-8278(01)00063-0. View

Petrovas C, Casazza J, Brenchley J, Price D, Gostick E, Adams W . PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med. 2006; 203(10):2281-92. PMC: 2118095. DOI: 10.1084/jem.20061496. View

Kosinska A, Johrden L, Zhang E, Fiedler M, Mayer A, Wildner O . DNA prime-adenovirus boost immunization induces a vigorous and multifunctional T-cell response against hepadnaviral proteins in the mouse and woodchuck model. J Virol. 2012; 86(17):9297-310. PMC: 3416123. DOI: 10.1128/JVI.00506-12. View

Mancini-Bourgine M, Fontaine H, Brechot C, Pol S, Michel M . Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. Vaccine. 2005; 24(21):4482-9. DOI: 10.1016/j.vaccine.2005.08.013. View

Dahmen A, Bocher W, Galle P, Lohr H . Clinical and immunological efficacy of intradermal vaccine plus lamivudine with or without interleukin-2 in patients with chronic hepatitis B. J Med Virol. 2002; 66(4):452-60. DOI: 10.1002/jmv.2165. View

Dandri M, Locarnini S . New insight in the pathobiology of hepatitis B virus infection. Gut. 2012; 61 Suppl 1:i6-17. DOI: 10.1136/gutjnl-2012-302056. View

Wen Y, Wu X, Hu D, Zhang Q, Guo S . Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy. Lancet. 1995; 345(8964):1575-6. DOI: 10.1016/s0140-6736(95)91126-x. View

Robinson H . New hope for an AIDS vaccine. Nat Rev Immunol. 2002; 2(4):239-50. DOI: 10.1038/nri776. View

Safadi R, Israeli E, Papo O, Shibolet O, Melhem A, Bloch A . Treatment of chronic hepatitis B virus infection via oral immune regulation toward hepatitis B virus proteins. Am J Gastroenterol. 2003; 98(11):2505-15. DOI: 10.1111/j.1572-0241.2003.07700.x. View

10.

Finnefrock A, Tang A, Li F, Freed D, Feng M, Cox K . PD-1 blockade in rhesus macaques: impact on chronic infection and prophylactic vaccination. J Immunol. 2009; 182(2):980-7. DOI: 10.4049/jimmunol.182.2.980. View

11.

Barber D, Wherry E, Masopust D, Zhu B, Allison J, Sharpe A . Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2005; 439(7077):682-7. DOI: 10.1038/nature04444. View

12.

Wang X, Zhang X, Yao X, Jiang J, Xie Y, Yuan Z . Serum HBeAg sero-conversion correlated with decrease of HBsAg and HBV DNA in chronic hepatitis B patients treated with a therapeutic vaccine. Vaccine. 2010; 28(51):8169-74. DOI: 10.1016/j.vaccine.2010.09.093. View

13.

Xu D, Wang X, Shen X, Gong G, Ren H, Guo L . Results of a phase III clinical trial with an HBsAg-HBIG immunogenic complex therapeutic vaccine for chronic hepatitis B patients: experiences and findings. J Hepatol. 2013; 59(3):450-6. DOI: 10.1016/j.jhep.2013.05.003. View

14.

Locarnini S, Mason W . Cellular and virological mechanisms of HBV drug resistance. J Hepatol. 2005; 44(2):422-31. DOI: 10.1016/j.jhep.2005.11.036. View

15.

Yang P, Althage A, Chung J, Maier H, Wieland S, Isogawa M . Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci U S A. 2010; 107(2):798-802. PMC: 2818933. DOI: 10.1073/pnas.0913498107. View

16.

Paoletti E . Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci U S A. 1996; 93(21):11349-53. PMC: 38060. DOI: 10.1073/pnas.93.21.11349. View

17.

Menne S, Roneker C, Tennant B, Korba B, Gerin J, Cote P . Immunogenic effects of woodchuck hepatitis virus surface antigen vaccine in combination with antiviral therapy: breaking of humoral and cellular immune tolerance in chronic woodchuck hepatitis virus infection. Intervirology. 2003; 45(4-6):237-50. DOI: 10.1159/000067914. View

18.

Boni C, Bertoletti A, Penna A, Cavalli A, Pilli M, Urbani S . Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest. 1998; 102(5):968-75. PMC: 508962. DOI: 10.1172/JCI3731. View

19.

Fiedler M, Kosinska A, Schumann A, Brovko O, Walker A, Lu M . Prime/boost immunization with DNA and adenoviral vectors protects from hepatitis D virus (HDV) infection after simultaneous infection with HDV and woodchuck hepatitis virus. J Virol. 2013; 87(13):7708-16. PMC: 3700281. DOI: 10.1128/JVI.00645-13. View

20.

Zoulim F, Locarnini S . Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology. 2009; 137(5):1593-608.e1-2. DOI: 10.1053/j.gastro.2009.08.063. View